Eli Lilly And Co (NYSE:LLY) SVP Alfonso G. Zulueta sold 10,000 shares of Eli Lilly And Co stock in a transaction dated Friday, April 12th. The stock was sold at an average price of $124.65, for a total value of $1,246,500.00. Following the transaction, the senior vice president now directly owns 57,806 shares in the company, valued at $7,205,517.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
NYSE LLY traded up $0.42 during trading on Friday, hitting $116.22. The company’s stock had a trading volume of 3,660,485 shares, compared to its average volume of 5,624,887. The company has a quick ratio of 0.85, a current ratio of 1.12 and a debt-to-equity ratio of 5.50. The company has a market cap of $112.42 billion, a P/E ratio of 20.94, a P/E/G ratio of 2.05 and a beta of 0.27. Eli Lilly And Co has a 52 week low of $80.96 and a 52 week high of $132.13.
Eli Lilly And Co (NYSE:LLY) last issued its quarterly earnings results on Tuesday, April 30th. The company reported $1.33 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.32 by $0.01. The company had revenue of $5.09 billion for the quarter, compared to the consensus estimate of $5.12 billion. Eli Lilly And Co had a return on equity of 56.62% and a net margin of 26.13%. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period in the previous year, the business posted $1.31 EPS. Sell-side analysts expect that Eli Lilly And Co will post 5.66 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Athena Capital Advisors LLC bought a new stake in shares of Eli Lilly And Co during the fourth quarter valued at approximately $26,000. Wakefield Asset Management LLLP bought a new stake in Eli Lilly And Co in the fourth quarter valued at $27,000. Trust Department MB Financial Bank N A grew its position in Eli Lilly And Co by 54.7% in the first quarter. Trust Department MB Financial Bank N A now owns 232 shares of the company’s stock valued at $30,000 after acquiring an additional 82 shares during the period. Larson Financial Group LLC bought a new stake in Eli Lilly And Co in the fourth quarter valued at $29,000. Finally, Ironwood Financial llc bought a new stake in Eli Lilly And Co in the fourth quarter valued at $30,000. Institutional investors and hedge funds own 79.17% of the company’s stock.
A number of equities analysts recently weighed in on the company. TheStreet cut Eli Lilly And Co from a “b+” rating to a “c+” rating in a research note on Thursday. BMO Capital Markets raised their price objective on Eli Lilly And Co from $130.00 to $133.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 1st. Cantor Fitzgerald restated a “buy” rating and set a $143.00 price objective on shares of Eli Lilly And Co in a research report on Tuesday, April 30th. Edward Jones upgraded Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $117.49 price objective for the company in a research report on Tuesday, April 23rd. Finally, Barclays reiterated a “buy” rating and set a $140.00 price target on shares of Eli Lilly And Co in a report on Sunday, April 14th. Ten investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $118.83.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Recommended Story: How Investors Use a Balance Sheet
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.